PSN
sodium hyaluronate 0.1 % Ophthalmic Drops
Prescribable Name
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.
Sodium Hyaluronate Eye Drops Liquid
RxNorm Crosswalk NDC 87298-037
View RxNorm Concepts, RxCUIs, and Term Type mappings for this NDC
RxNorm Mapping Clinical Concepts
The product Sodium Hyaluronate Eye Drops (NDC 87298-037) is cross-mapped to the RxNorm terminology system to ensure clinical interoperability. This formulation is linked to a unique clinical concept (RxCUI 2743151). By anchoring Guangzhou Hechuang Commercial Service Co.,ltd.'s product data to these standardized identifiers, healthcare systems can maintain accurate medication records, safely automate e-prescribing, and streamline pharmacy workflows.
The following clinical concept cards detail the semantic term types (TTY), prescribable names, and synonymous clinical strings as defined by the National Library of Medicine (NLM).
SCD
Featured Concept
sodium hyaluronate 1 MG/ML Ophthalmic Solution
(RxCUI 2743151)
Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.
Understanding RxNorm Mapping for Sodium Hyaluronate Eye Drops
RxNorm is a normalized naming system developed by the National Library of Medicine (NLM) to bridge the gap between different drug terminologies. By mapping NDC 87298-037 to RxCUI 2743151, this page provides the standardized "source of truth" required for hospital systems, e-prescribing software, and pharmacy benefit managers (PBMs) to communicate without errors.
Term Type (TTY) Legend for This Page
The clinical cards above utilize specific Term Types (TTY) to define the granularity of the drug concept:
- PSN Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.
- SCD Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.
* Please review the full disclaimer at the bottom of this page.
